title: Efficacy and safety of a purified porcine insulin zinc suspension for managing diabetes mellitus in dogs.
abstract: The objective of this study was to evaluate the safety and efficacy of a purified porcine insulin zinc suspension for treating dogs with uncomplicated diabetes mellitus. Fifty-three dogs were treated for 60 days after an initial dose determination period. The means of the blood glucose concentrations during 12-hour glucose curves and the means of the blood glucose nadir concentrations during 12-hour glucose curves for all dogs were determined before beginning insulin therapy (time 0), at the end of the dose determination period (time 1), 30 days after time 1 (time 2), and 60 days after time 1 (time 3). Presence of polyuria, polydipsia, and ketonuria was determined at each time point. Adequacy of control of hyperglycemia was based on 12-hour blood glucose curves and improvement in clinical variables (results of physical examinations, historic information, polyuria, polydipsia, and ketonuria). Safety was evaluated by questionnaire, performance of physical examination, CBC, serum chemistry profile, and urinalysis. The means of the blood glucose concentrations during 12-hour glucose curves and the means of the blood glucose nadir concentrations during 12-hour glucose curves for all dogs at times 1, 2, and 3 were significantly lower compared with time 0 (P < .0001). There was a reduction in the proportion of dogs with polyuria, polydipsia, and ketonuria of 82, 86, and 80%, respectively. All of the dogs had adequate glycemic control at time 1, 66% at time 2, and 75% at time 3. At time 3, 66% of dogs required insulin injections q12h. Other than hypoglycemia, there were no important adverse effects of insulin administration. The insulin, was safe and efficacious for reducing blood glucose and clinical signs in dogs with diabetes mellitus.
authors.affiliation: Department of Small Animal Clinical Sciences, VA-MD Regional College of Veterinary Medicine, Virginia Tech, Blacksburg, USA. monroewe@vt.edu
authors.forename: William E
authors.initials: WE
authors.lastname: Monroe
authors.forename: David
authors.initials: D
authors.lastname: Laxton
authors.forename: Edward A
authors.initials: EA
authors.lastname: Fallin
authors.forename: Keith P
authors.initials: KP
authors.lastname: Richter
authors.forename: Douglas R
authors.initials: DR
authors.lastname: Santen
authors.forename: David L
authors.initials: DL
authors.lastname: Panciera
authors.forename: Todd L
authors.initials: TL
authors.lastname: Towell
authors.forename: Kimberly A
authors.initials: KA
authors.lastname: Williams
authors.forename: John R
authors.initials: JR
authors.lastname: Hart
authors.forename: Steve
authors.initials: S
authors.lastname: Hill
authors.forename: Mark R
authors.initials: MR
authors.lastname: Finkler
authors.forename: Jennifer S
authors.initials: JS
authors.lastname: Shinn
mesh_terms: D000818:Animals; D019540:Area Under Curve; D001786:Blood Glucose / Q000187:drug effects* / Q000378:metabolism; D003920:Diabetes Mellitus / Q000188:drug therapy / Q000662:veterinary*; D004283:Dog Diseases / Q000188:drug therapy*; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D005260:Female; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007328:Insulin / Q000627:therapeutic use*; D008297:Male; D010808:Physical Examination / Q000662:veterinary; D012449:Safety; D016896:Treatment Outcome; D016482:Urinalysis / Q000662:veterinary
chemical_list: D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007328:Insulin